| Attributes | Values |
|---|
| rdf:type
| |
| http://linked.open...gbank/description
| - Nabumetone is a nonsteroidal anti-inflammatory drug (NSAID) of the arylalkanoic acid family (which includes diclofenac). Marketed under the brand name Relafen, it has been shown to have a slightly lower risk of gastrointestinal side effects than most other non-selective NSAIDs. (en)
|
| http://linked.open...y/drugbank/dosage
| |
| http://linked.open...gy/drugbank/group
| |
| http://linked.open...drugbank/halfLife
| - Approximately 23 hours for the active metabolite, 6MNA. Increased in patients with renal insufficiency. (en)
|
| http://linked.open...ugbank/indication
| - For acute and chronic treatment of signs and symptoms of osteoarthritis and rheumatoid arthritis. (en)
|
| http://linked.open...bank/manufacturer
| |
| sameAs
| |
| Title
| |
| adms:identifier
| |
| http://linked.open...mechanismOfAction
| - The parent compound is a prodrug, which undergoes hepatic biotransformation to the active component, 6-methoxy-2-naphthylacetic acid (6MNA), that is a potent inhibitor of prostaglandin synthesis, most likely through binding to the COX-2 and COX-1 receptors. (en)
|
| http://linked.open...drugbank/packager
| |
| http://linked.open...outeOfElimination
| - Approximately 35% of a 1000 mg oral dose of nabumetone is converted to 6MNA and 50% is converted into unidentified metabolites which are subsequently excreted in the urine. (en)
|
| http://linked.open.../drugbank/synonym
| - Nabumetone (en)
- Relafen (en)
- Nabumetona (en)
- 4-(6-Methoxy-2-naphthalenyl)-2-butanone (en)
- 4-(6-Methoxy-2-naphthyl)-2-butanone (en)
- Nabumeton (en)
- Nabumetonum (en)
- Nabumétone (en)
|
| http://linked.open...drugbank/toxicity
| - The one overdose occurred in a 17-year-old female patient who had a history of abdominal pain and was hospitalized for increased abdominal pain following ingestion of 30 nabumetone tablets (15 grams total). Stools were negative for occult blood and there was no fall in serum hemoglobin concentration. The patient had no other symptoms. (en)
|
| http://linked.open.../drug/hasAHFSCode
| |
| http://linked.open...k/foodInteraction
| - Avoid alcohol. (en)
- Take with food for faster absorption. (en)
|
| http://linked.open...nk/proteinBinding
| - The active metabolite, 6MNA, is more than 99% bound to plasma proteins. (en)
|
| http://linked.open...ynthesisReference
| - Brian F. Becnel, Mahmood Sabahi, Kevin J. Theriot, "Production of nabumetone or precursors thereof." U.S. Patent US5907069, issued December, 1985. (en)
|
| http://linked.open...y/mesh/hasConcept
| |
| foaf:page
| |
| http://linked.open...ugbank/IUPAC-Name
| |
| http://linked.open...gy/drugbank/InChI
| |
| http://linked.open...Molecular-Formula
| |
| http://linked.open.../Molecular-Weight
| |
| http://linked.open...noisotopic-Weight
| |
| http://linked.open...y/drugbank/SMILES
| |
| http://linked.open.../Water-Solubility
| |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)